
Potent and highly selective CDK9 inhibitor for treatment of hematologic malignancies
Researchers studied the effects of GFH009, a potent and selective CDK9 inhibitor, on the treatment of hematologic malignancies. GFH009 demonstrated antiproliferative activity in cell lines derived from human hematological malignancies, inhibiting tumor growth and inducing apoptosis. In preclinical models, GFH009 significantly prolonged the survival of rodents with the condition. The study found that GFH009 rapidly…